Compare GORO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | IFRX |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 60.6M |
| IPO Year | 2010 | 2017 |
| Metric | GORO | IFRX |
|---|---|---|
| Price | $1.32 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.75 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.0M | 171.7K |
| Earning Date | 04-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,726,000.00 | N/A |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.71 |
| 52 Week High | $1.87 | $1.94 |
| Indicator | GORO | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 52.69 |
| Support Level | $1.27 | $0.75 |
| Resistance Level | $1.75 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.75 | 50.85 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.